Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
J W Liu, T Shiiba, R Kondo, S Harti, A Mello and G Cauwenbergh
Posters-Accepted Abstracts: J Clin Exp Dermatol Res
Chemotherapy induced alopecia (CIA), with 65% incidence, is among the most distressing side effects of cancer therapies. About 70% of cancer survivors still complain from persistent hair issues several years after hair regrowth. In human scalp biopsy, we demonstrated that the product, a topical botanical lotion, normalized follicular cell apoptosis process and attenuated scalp micro-inflammation, two unresolved key issues in the management of CIA and chemotherapy persistent hair disorders (CPHD). To further assess the product potential for CIA and CPHD, we conducted two pilot studies aiming at: �?� Efficacy in reducing CIA baldness period �?� Recovery from CPHD, especially improvement of hair thinning and hair volume. The first study (n=9) in female cancer patients treated with chemotherapy (docetaxel, etc.) showed that topical application of the product allowed faster hair recovery (5-16 weeks quicker than historical control). Note that the baldness period, from maximum hair loss to first hair regrowth, lasts 20 weeks on average in non-treated references. The second study (n=21) in cancer survivors complaining from CPHD several years after chemotherapy revealed that first improvement was observed in 33%, 52% and 76% of subjects after 1, 2 and 3 months, respectively, following product application. Good compliance with product use (twice-daily), and no side effect was reported in both studies. Although larger sample size studies are needed, the initial outcome showed that topical product application reduced baldness period in cancer patients treated with alopecia chemo-agents, improved hair pattern in most subjects complaining from CPHD, as early as 1-3 months.